Share Price and Basic Stock Data
Last Updated: November 22, 2025, 8:33 am
| PEG Ratio | 1.19 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Genesys International Corporation Ltd operates in the IT Consulting & Software sector, with a current market capitalization of ₹1,907 Cr and a share price of ₹457. The company reported total sales of ₹181 Cr in FY 2023, increasing to ₹198 Cr in FY 2024, and is projected to rise significantly to ₹311 Cr in FY 2025. The trailing twelve months (TTM) sales stood at ₹331 Cr, indicating a robust growth trajectory. Quarterly sales have shown volatility, peaking at ₹71.17 Cr in Mar 2024, reflecting the company’s capacity to scale operations effectively. Despite a dip in sales to ₹34.55 Cr in Jun 2023, the subsequent recovery to ₹59.34 Cr in Dec 2023 showcases resilience in revenue generation. The overall trend highlights a strong rebound, with future sales expected to maintain momentum as the company continues to capitalize on growth opportunities in the IT sector.
Profitability and Efficiency Metrics
Genesys International reported an operating profit margin (OPM) of 41.63% for FY 2025, showcasing strong operational efficiency. The company recorded an operating profit of ₹143 Cr for the same fiscal year, an increase from ₹81 Cr in FY 2024. The net profit for FY 2025 stood at ₹56 Cr, up from ₹22 Cr in FY 2024, resulting in an earnings per share (EPS) of ₹14.12. The return on equity (ROE) is reported at 10.8%, while return on capital employed (ROCE) is at 15.0%, indicating effective utilization of shareholders’ equity and capital. The interest coverage ratio (ICR) stood impressively at 16.68x, reflecting the company’s ability to meet interest obligations comfortably. Despite fluctuations in quarterly profits, notably a loss of ₹5.46 Cr in Jun 2023, the overall profitability metrics signify a strong rebound and healthy financial health.
Balance Sheet Strength and Financial Ratios
Genesys International’s balance sheet illustrates a robust financial position, with total assets amounting to ₹778 Cr and reserves of ₹536 Cr as of Mar 2025. The company’s borrowings are relatively low at ₹122 Cr, resulting in a debt-to-equity ratio of 0.19, suggesting a conservative leverage approach. The current and quick ratios are reported at 2.41, indicating strong liquidity and an ability to cover short-term liabilities. The price-to-book value ratio stands at 5.15x, reflecting investor confidence in the company’s growth potential. Additionally, the cash conversion cycle is at 261 days, which, while higher than previous years, suggests a focus on managing receivables effectively. The overall financial ratios position Genesys International favorably against industry norms, enhancing its creditworthiness and operational stability.
Shareholding Pattern and Investor Confidence
As of Mar 2025, Genesys International’s shareholding pattern indicates a diverse investor base, with promoters holding 33.08% of the shares, down from 39.70% in Mar 2023. Foreign institutional investors (FIIs) account for 5.11%, a notable decrease from 6.50% previously, while domestic institutional investors (DIIs) hold 0.68%. The public shareholding has increased to 61.13%, reflecting growing retail investor interest and confidence in the company. The number of shareholders has risen significantly from 7,401 in Dec 2022 to 38,243 in Mar 2025, indicating a broader acceptance and interest in the stock. This shift suggests that while promoter confidence may have waned slightly, the overall market perception remains positive, helping to bolster the company’s market valuation and liquidity.
Outlook, Risks, and Final Insight
Looking ahead, Genesys International is poised for continued growth, driven by expanding revenue streams and improving profitability metrics. However, risks such as fluctuating operational performance, particularly in quarterly sales, and potential market volatility could impact future earnings. The company’s reliance on a strong public investor base may present challenges if sentiment shifts. Additionally, maintaining operational efficiency will be critical in sustaining margins amidst rising costs. Should the company successfully navigate these challenges, it stands to further solidify its position in the IT consulting space. Conversely, any significant downturn in market conditions or operational disruptions could pose risks to its growth trajectory. Overall, Genesys International’s strong financial foundation and improving profitability metrics provide a solid basis for future performance.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Genesys International Corporation Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Naapbooks Ltd | 156 Cr. | 145 | 194/99.8 | 23.9 | 36.4 | 0.00 % | 23.6 % | 17.1 % | 10.0 |
| IB Infotech Enterprises Ltd | 26.5 Cr. | 207 | 310/140 | 18.9 | 26.7 | 0.48 % | 38.5 % | 35.4 % | 10.0 |
| Hit Kit Global Solutions Ltd | 5.29 Cr. | 1.08 | 1.73/0.91 | 2.47 | 0.00 % | 2.14 % | 2.15 % | 2.00 | |
| Globalspace Technologies Ltd | 57.5 Cr. | 16.7 | 25.0/13.7 | 103 | 15.8 | 0.00 % | 2.13 % | 1.41 % | 10.0 |
| First Fintec Ltd | 7.09 Cr. | 6.82 | 11.7/5.25 | 88.6 | 10.3 | 0.00 % | 0.28 % | 0.85 % | 10.0 |
| Industry Average | 19,958.08 Cr | 574.21 | 91.41 | 126.08 | 0.56% | 14.93% | 20.42% | 6.95 |
All Competitor Stocks of Genesys International Corporation Ltd
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 42.69 | 37.38 | 54.43 | 46.62 | 34.55 | 33.19 | 59.34 | 71.17 | 55.76 | 72.02 | 89.09 | 94.16 | 70.87 |
| Expenses | 30.95 | 26.42 | 35.07 | 30.30 | 28.75 | 25.49 | 28.56 | 34.92 | 35.35 | 42.64 | 46.52 | 44.39 | 41.37 |
| Operating Profit | 11.74 | 10.96 | 19.36 | 16.32 | 5.80 | 7.70 | 30.78 | 36.25 | 20.41 | 29.38 | 42.57 | 49.77 | 29.50 |
| OPM % | 27.50% | 29.32% | 35.57% | 35.01% | 16.79% | 23.20% | 51.87% | 50.93% | 36.60% | 40.79% | 47.78% | 52.86% | 41.63% |
| Other Income | 1.37 | 1.93 | 1.79 | 1.41 | 0.93 | 1.11 | 2.53 | 0.46 | 1.41 | 1.00 | 1.84 | 0.11 | 1.27 |
| Interest | 0.54 | 0.56 | 0.35 | 1.22 | 0.67 | 0.72 | 1.09 | 1.43 | 1.24 | 1.88 | 2.58 | 3.08 | 3.18 |
| Depreciation | 8.14 | 8.90 | 9.30 | 10.86 | 11.30 | 10.94 | 11.06 | 11.18 | 11.80 | 12.25 | 15.69 | 15.29 | 15.43 |
| Profit before tax | 4.43 | 3.43 | 11.50 | 5.65 | -5.24 | -2.85 | 21.16 | 24.10 | 8.78 | 16.25 | 26.14 | 31.51 | 12.16 |
| Tax % | 55.53% | 5.83% | 32.70% | 64.42% | 4.39% | 20.70% | 25.71% | 38.63% | 39.64% | 31.69% | 20.73% | 39.73% | 42.60% |
| Net Profit | 1.97 | 3.23 | 7.73 | 2.00 | -5.46 | -3.43 | 15.73 | 14.79 | 5.30 | 11.09 | 20.71 | 19.00 | 6.98 |
| EPS in Rs | 1.36 | 1.30 | 2.13 | 0.57 | -1.41 | -0.87 | 4.19 | 3.76 | 1.36 | 2.83 | 5.20 | 4.76 | 1.71 |
Last Updated: August 20, 2025, 10:30 am
Below is a detailed analysis of the quarterly data for Genesys International Corporation Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 70.87 Cr.. The value appears to be declining and may need further review. It has decreased from 94.16 Cr. (Mar 2025) to 70.87 Cr., marking a decrease of 23.29 Cr..
- For Expenses, as of Jun 2025, the value is 41.37 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 44.39 Cr. (Mar 2025) to 41.37 Cr., marking a decrease of 3.02 Cr..
- For Operating Profit, as of Jun 2025, the value is 29.50 Cr.. The value appears to be declining and may need further review. It has decreased from 49.77 Cr. (Mar 2025) to 29.50 Cr., marking a decrease of 20.27 Cr..
- For OPM %, as of Jun 2025, the value is 41.63%. The value appears to be declining and may need further review. It has decreased from 52.86% (Mar 2025) to 41.63%, marking a decrease of 11.23%.
- For Other Income, as of Jun 2025, the value is 1.27 Cr.. The value appears strong and on an upward trend. It has increased from 0.11 Cr. (Mar 2025) to 1.27 Cr., marking an increase of 1.16 Cr..
- For Interest, as of Jun 2025, the value is 3.18 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.08 Cr. (Mar 2025) to 3.18 Cr., marking an increase of 0.10 Cr..
- For Depreciation, as of Jun 2025, the value is 15.43 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 15.29 Cr. (Mar 2025) to 15.43 Cr., marking an increase of 0.14 Cr..
- For Profit before tax, as of Jun 2025, the value is 12.16 Cr.. The value appears to be declining and may need further review. It has decreased from 31.51 Cr. (Mar 2025) to 12.16 Cr., marking a decrease of 19.35 Cr..
- For Tax %, as of Jun 2025, the value is 42.60%. The value appears to be increasing, which may not be favorable. It has increased from 39.73% (Mar 2025) to 42.60%, marking an increase of 2.87%.
- For Net Profit, as of Jun 2025, the value is 6.98 Cr.. The value appears to be declining and may need further review. It has decreased from 19.00 Cr. (Mar 2025) to 6.98 Cr., marking a decrease of 12.02 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.71. The value appears to be declining and may need further review. It has decreased from 4.76 (Mar 2025) to 1.71, marking a decrease of 3.05.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 5:21 am
| Metric | Mar 2011 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 95 | 60 | 47 | 64 | 114 | 115 | 112 | 80 | 120 | 181 | 198 | 311 | 331 |
| Expenses | 42 | 47 | 40 | 48 | 78 | 96 | 98 | 81 | 92 | 122 | 117 | 168 | 179 |
| Operating Profit | 53 | 13 | 7 | 16 | 36 | 19 | 13 | -2 | 28 | 59 | 81 | 143 | 152 |
| OPM % | 56% | 21% | 16% | 25% | 32% | 17% | 12% | -2% | 23% | 32% | 41% | 46% | 46% |
| Other Income | -1 | 2 | 6 | 3 | 4 | 3 | 4 | -30 | -42 | 6 | 5 | 4 | 7 |
| Interest | 0 | 2 | 2 | 2 | 2 | 3 | 3 | 4 | 3 | 3 | 5 | 10 | 12 |
| Depreciation | 7 | 8 | 7 | 13 | 14 | 19 | 21 | 19 | 19 | 37 | 44 | 55 | 62 |
| Profit before tax | 45 | 5 | 5 | 5 | 24 | 0 | -7 | -54 | -36 | 25 | 37 | 83 | 85 |
| Tax % | -1% | 11% | 6% | -41% | 28% | 1,108% | -23% | -5% | 11% | 40% | 42% | 32% | |
| Net Profit | 46 | 4 | 2 | 6 | 17 | -4 | -5 | -52 | -40 | 15 | 22 | 56 | 59 |
| EPS in Rs | 15.42 | 1.43 | 0.73 | 2.11 | 5.50 | 1.73 | 0.61 | -13.75 | 4.28 | 5.05 | 5.58 | 14.12 | 14.55 |
| Dividend Payout % | 8% | 9% | 17% | 6% | 2% | 7% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -50.00% | 200.00% | 183.33% | -123.53% | -25.00% | -940.00% | 23.08% | 137.50% | 46.67% | 154.55% |
| Change in YoY Net Profit Growth (%) | 0.00% | 250.00% | -16.67% | -306.86% | 98.53% | -915.00% | 963.08% | 114.42% | -90.83% | 107.88% |
Genesys International Corporation Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2015-2016 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 23% |
| 3 Years: | 38% |
| TTM: | 49% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 29% |
| 5 Years: | 98% |
| 3 Years: | -3% |
| TTM: | 77% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 29% |
| 5 Years: | 63% |
| 3 Years: | 1% |
| 1 Year: | -25% |
| Return on Equity | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 8% |
| 3 Years: | 7% |
| Last Year: | 11% |
Last Updated: September 5, 2025, 4:40 am
Balance Sheet
Last Updated: November 9, 2025, 2:03 pm
| Month | Mar 2011 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15 | 15 | 15 | 15 | 15 | 16 | 16 | 16 | 16 | 19 | 20 | 20 |
| Reserves | 126 | 193 | 195 | 152 | 209 | 208 | 197 | 158 | 189 | 387 | 469 | 536 |
| Borrowings | 2 | 12 | 14 | 22 | 24 | 26 | 16 | 14 | 26 | 39 | 60 | 122 |
| Other Liabilities | 23 | 25 | 37 | 135 | 136 | 134 | 136 | 117 | 88 | 61 | 86 | 100 |
| Total Liabilities | 165 | 244 | 262 | 324 | 385 | 383 | 365 | 304 | 319 | 506 | 635 | 778 |
| Fixed Assets | 46 | 21 | 22 | 179 | 217 | 208 | 203 | 194 | 138 | 157 | 156 | 128 |
| CWIP | -0 | -0 | -0 | -0 | 0 | -0 | -0 | -0 | 19 | 65 | 113 | 156 |
| Investments | 8 | 122 | 156 | 25 | 11 | 11 | 15 | 8 | 6 | 51 | -0 | -0 |
| Other Assets | 111 | 101 | 84 | 120 | 157 | 165 | 147 | 102 | 156 | 232 | 366 | 495 |
| Total Assets | 165 | 244 | 262 | 324 | 385 | 383 | 365 | 304 | 319 | 506 | 635 | 778 |
Below is a detailed analysis of the balance sheet data for Genesys International Corporation Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 20.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 20.00 Cr..
- For Reserves, as of Mar 2025, the value is 536.00 Cr.. The value appears strong and on an upward trend. It has increased from 469.00 Cr. (Mar 2024) to 536.00 Cr., marking an increase of 67.00 Cr..
- For Borrowings, as of Mar 2025, the value is 122.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 60.00 Cr. (Mar 2024) to 122.00 Cr., marking an increase of 62.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 100.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 86.00 Cr. (Mar 2024) to 100.00 Cr., marking an increase of 14.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 778.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 635.00 Cr. (Mar 2024) to 778.00 Cr., marking an increase of 143.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 128.00 Cr.. The value appears to be declining and may need further review. It has decreased from 156.00 Cr. (Mar 2024) to 128.00 Cr., marking a decrease of 28.00 Cr..
- For CWIP, as of Mar 2025, the value is 156.00 Cr.. The value appears strong and on an upward trend. It has increased from 113.00 Cr. (Mar 2024) to 156.00 Cr., marking an increase of 43.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 495.00 Cr.. The value appears strong and on an upward trend. It has increased from 366.00 Cr. (Mar 2024) to 495.00 Cr., marking an increase of 129.00 Cr..
- For Total Assets, as of Mar 2025, the value is 778.00 Cr.. The value appears strong and on an upward trend. It has increased from 635.00 Cr. (Mar 2024) to 778.00 Cr., marking an increase of 143.00 Cr..
Notably, the Reserves (536.00 Cr.) exceed the Borrowings (122.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2011 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2011 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 51.00 | 1.00 | -7.00 | -6.00 | 12.00 | -7.00 | -3.00 | -16.00 | 2.00 | 20.00 | 21.00 | 21.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2011 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 120 | 343 | 219 | 132 | 134 | 186 | 155 | 148 | 150 | 168 | 263 | 261 |
| Inventory Days | ||||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 120 | 343 | 219 | 132 | 134 | 186 | 155 | 148 | 150 | 168 | 263 | 261 |
| Working Capital Days | 172 | 326 | 172 | 105 | 99 | 215 | 223 | 126 | 82 | 212 | 269 | 291 |
| ROCE % | 41% | 3% | 3% | 8% | 1% | -1% | -7% | 4% | 7% | 8% | 15% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Basic EPS (Rs.) | 14.14 | 5.78 | 5.44 | 4.28 | -13.77 |
| Diluted EPS (Rs.) | 14.03 | 5.74 | 5.29 | 4.28 | -13.34 |
| Cash EPS (Rs.) | 27.92 | 16.72 | 13.81 | -6.55 | -10.57 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 139.57 | 124.12 | 107.93 | 75.21 | 81.64 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 139.57 | 124.12 | 107.93 | 75.21 | 81.64 |
| Revenue From Operations / Share (Rs.) | 78.14 | 50.14 | 47.97 | 38.14 | 25.48 |
| PBDIT / Share (Rs.) | 36.80 | 21.64 | 17.18 | 9.83 | -0.49 |
| PBIT / Share (Rs.) | 22.98 | 10.39 | 7.33 | 3.74 | -6.51 |
| PBT / Share (Rs.) | 20.77 | 9.40 | 6.62 | -11.44 | -17.43 |
| Net Profit / Share (Rs.) | 14.10 | 5.47 | 3.95 | -12.65 | -16.59 |
| NP After MI And SOA / Share (Rs.) | 14.13 | 5.58 | 5.05 | 4.28 | -13.75 |
| PBDIT Margin (%) | 47.09 | 43.16 | 35.81 | 25.78 | -1.95 |
| PBIT Margin (%) | 29.40 | 20.72 | 15.27 | 9.79 | -25.53 |
| PBT Margin (%) | 26.58 | 18.75 | 13.79 | -29.98 | -68.43 |
| Net Profit Margin (%) | 18.03 | 10.90 | 8.24 | -33.17 | -65.09 |
| NP After MI And SOA Margin (%) | 18.07 | 11.13 | 10.53 | 11.21 | -53.96 |
| Return on Networth / Equity (%) | 10.12 | 4.51 | 4.70 | 6.54 | -24.77 |
| Return on Capital Employeed (%) | 15.53 | 7.81 | 6.33 | 4.76 | -7.59 |
| Return On Assets (%) | 7.22 | 3.47 | 3.77 | 4.17 | -14.11 |
| Long Term Debt / Equity (X) | 0.02 | 0.04 | 0.04 | 0.01 | 0.00 |
| Total Debt / Equity (X) | 0.19 | 0.10 | 0.07 | 0.09 | 0.03 |
| Asset Turnover Ratio (%) | 0.44 | 0.34 | 0.43 | 0.41 | 0.23 |
| Current Ratio (X) | 2.41 | 3.04 | 3.52 | 1.73 | 2.13 |
| Quick Ratio (X) | 2.41 | 3.04 | 3.52 | 1.73 | 2.13 |
| Interest Coverage Ratio (X) | 16.68 | 21.89 | 24.33 | 12.45 | -0.53 |
| Interest Coverage Ratio (Post Tax) (X) | 7.39 | 6.53 | 6.60 | 3.19 | -6.06 |
| Enterprise Value (Cr.) | 2956.65 | 2312.97 | 1258.23 | 1817.61 | 404.10 |
| EV / Net Operating Revenue (X) | 9.51 | 11.67 | 6.95 | 15.19 | 5.08 |
| EV / EBITDA (X) | 20.18 | 27.03 | 19.40 | 58.93 | -260.36 |
| MarketCap / Net Operating Revenue (X) | 9.21 | 11.78 | 6.86 | 14.95 | 4.02 |
| Price / BV (X) | 5.15 | 4.78 | 3.06 | 8.73 | 1.84 |
| Price / Net Operating Revenue (X) | 9.21 | 11.78 | 6.86 | 14.95 | 4.02 |
| EarningsYield | 0.01 | 0.01 | 0.01 | 0.01 | -0.13 |
After reviewing the key financial ratios for Genesys International Corporation Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 14.14. This value is within the healthy range. It has increased from 5.78 (Mar 24) to 14.14, marking an increase of 8.36.
- For Diluted EPS (Rs.), as of Mar 25, the value is 14.03. This value is within the healthy range. It has increased from 5.74 (Mar 24) to 14.03, marking an increase of 8.29.
- For Cash EPS (Rs.), as of Mar 25, the value is 27.92. This value is within the healthy range. It has increased from 16.72 (Mar 24) to 27.92, marking an increase of 11.20.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 139.57. It has increased from 124.12 (Mar 24) to 139.57, marking an increase of 15.45.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 139.57. It has increased from 124.12 (Mar 24) to 139.57, marking an increase of 15.45.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 78.14. It has increased from 50.14 (Mar 24) to 78.14, marking an increase of 28.00.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 36.80. This value is within the healthy range. It has increased from 21.64 (Mar 24) to 36.80, marking an increase of 15.16.
- For PBIT / Share (Rs.), as of Mar 25, the value is 22.98. This value is within the healthy range. It has increased from 10.39 (Mar 24) to 22.98, marking an increase of 12.59.
- For PBT / Share (Rs.), as of Mar 25, the value is 20.77. This value is within the healthy range. It has increased from 9.40 (Mar 24) to 20.77, marking an increase of 11.37.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 14.10. This value is within the healthy range. It has increased from 5.47 (Mar 24) to 14.10, marking an increase of 8.63.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 14.13. This value is within the healthy range. It has increased from 5.58 (Mar 24) to 14.13, marking an increase of 8.55.
- For PBDIT Margin (%), as of Mar 25, the value is 47.09. This value is within the healthy range. It has increased from 43.16 (Mar 24) to 47.09, marking an increase of 3.93.
- For PBIT Margin (%), as of Mar 25, the value is 29.40. This value exceeds the healthy maximum of 20. It has increased from 20.72 (Mar 24) to 29.40, marking an increase of 8.68.
- For PBT Margin (%), as of Mar 25, the value is 26.58. This value is within the healthy range. It has increased from 18.75 (Mar 24) to 26.58, marking an increase of 7.83.
- For Net Profit Margin (%), as of Mar 25, the value is 18.03. This value exceeds the healthy maximum of 10. It has increased from 10.90 (Mar 24) to 18.03, marking an increase of 7.13.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 18.07. This value is within the healthy range. It has increased from 11.13 (Mar 24) to 18.07, marking an increase of 6.94.
- For Return on Networth / Equity (%), as of Mar 25, the value is 10.12. This value is below the healthy minimum of 15. It has increased from 4.51 (Mar 24) to 10.12, marking an increase of 5.61.
- For Return on Capital Employeed (%), as of Mar 25, the value is 15.53. This value is within the healthy range. It has increased from 7.81 (Mar 24) to 15.53, marking an increase of 7.72.
- For Return On Assets (%), as of Mar 25, the value is 7.22. This value is within the healthy range. It has increased from 3.47 (Mar 24) to 7.22, marking an increase of 3.75.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. It has decreased from 0.04 (Mar 24) to 0.02, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.19. This value is within the healthy range. It has increased from 0.10 (Mar 24) to 0.19, marking an increase of 0.09.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.44. It has increased from 0.34 (Mar 24) to 0.44, marking an increase of 0.10.
- For Current Ratio (X), as of Mar 25, the value is 2.41. This value is within the healthy range. It has decreased from 3.04 (Mar 24) to 2.41, marking a decrease of 0.63.
- For Quick Ratio (X), as of Mar 25, the value is 2.41. This value exceeds the healthy maximum of 2. It has decreased from 3.04 (Mar 24) to 2.41, marking a decrease of 0.63.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 16.68. This value is within the healthy range. It has decreased from 21.89 (Mar 24) to 16.68, marking a decrease of 5.21.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.39. This value is within the healthy range. It has increased from 6.53 (Mar 24) to 7.39, marking an increase of 0.86.
- For Enterprise Value (Cr.), as of Mar 25, the value is 2,956.65. It has increased from 2,312.97 (Mar 24) to 2,956.65, marking an increase of 643.68.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 9.51. This value exceeds the healthy maximum of 3. It has decreased from 11.67 (Mar 24) to 9.51, marking a decrease of 2.16.
- For EV / EBITDA (X), as of Mar 25, the value is 20.18. This value exceeds the healthy maximum of 15. It has decreased from 27.03 (Mar 24) to 20.18, marking a decrease of 6.85.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 9.21. This value exceeds the healthy maximum of 3. It has decreased from 11.78 (Mar 24) to 9.21, marking a decrease of 2.57.
- For Price / BV (X), as of Mar 25, the value is 5.15. This value exceeds the healthy maximum of 3. It has increased from 4.78 (Mar 24) to 5.15, marking an increase of 0.37.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 9.21. This value exceeds the healthy maximum of 3. It has decreased from 11.78 (Mar 24) to 9.21, marking a decrease of 2.57.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Genesys International Corporation Ltd:
- Net Profit Margin: 18.03%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 15.53% (Industry Average ROCE: 14.93%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 10.12% (Industry Average ROE: 20.42%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 7.39
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.41
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 33.1 (Industry average Stock P/E: 91.41)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.19
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 18.03%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| IT Consulting & Software | 73-A, SDF-III, SEEPZ, Mumbai Maharashtra 400096 | investors@igenesys.com http://www.igenesys.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sajid Malik | Chairman & Managing Director |
| Ms. Bharti Sinha | Independent Director |
| Mr. Manish Patel | Independent Director |
| Mr. Ajay Aggarwal | Independent Director |
| Mr. Omprakash Hemrajani | Director |
| Dr. Yogita Shukla | Director |
FAQ
What is the intrinsic value of Genesys International Corporation Ltd?
Genesys International Corporation Ltd's intrinsic value (as of 25 November 2025) is 478.39 which is 2.88% higher the current market price of 465.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 1,942 Cr. market cap, FY2025-2026 high/low of 1,055/430, reserves of ₹536 Cr, and liabilities of 778 Cr.
What is the Market Cap of Genesys International Corporation Ltd?
The Market Cap of Genesys International Corporation Ltd is 1,942 Cr..
What is the current Stock Price of Genesys International Corporation Ltd as on 25 November 2025?
The current stock price of Genesys International Corporation Ltd as on 25 November 2025 is 465.
What is the High / Low of Genesys International Corporation Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Genesys International Corporation Ltd stocks is 1,055/430.
What is the Stock P/E of Genesys International Corporation Ltd?
The Stock P/E of Genesys International Corporation Ltd is 33.1.
What is the Book Value of Genesys International Corporation Ltd?
The Book Value of Genesys International Corporation Ltd is 164.
What is the Dividend Yield of Genesys International Corporation Ltd?
The Dividend Yield of Genesys International Corporation Ltd is 0.00 %.
What is the ROCE of Genesys International Corporation Ltd?
The ROCE of Genesys International Corporation Ltd is 15.0 %.
What is the ROE of Genesys International Corporation Ltd?
The ROE of Genesys International Corporation Ltd is 10.8 %.
What is the Face Value of Genesys International Corporation Ltd?
The Face Value of Genesys International Corporation Ltd is 5.00.